Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 6/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.44 |
| ▸ | EP300 | Q09472 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943211 | 0.78 | KDM1A (0.42) | EP300KDM1AACACB | |
| SCHEMBL28408353 | 0.77 | KDM1A (0.37) | EP300KDM1AACACB | |
| SCHEMBL12248343 | 0.77 | ACACB (0.39) | EP300KDM1AACACB | |
| SCHEMBL2698965 | 0.76 | EP300 (0.46) | EP300KDM1AACACBPARP15PARP10 | |
| SCHEMBL30126846 | 0.76 | EP300 (0.46) | EP300KDM1AACACBPARP15PARP10 | |
| SCHEMBL16838835 | 0.73 | ACACB (0.37) | EP300KDM1AACACBPARP15PARP10 | |
| SCHEMBL20469409 | 0.73 | EP300 (0.42) | EP300KDM1AACACB | |
| SCHEMBL32671900 | 0.72 | FEN1 (0.39) | FEN1ALOX5AP | |
| SCHEMBL31508214 | 0.72 | FEN1 (0.39) | FEN1ALOX5AP | |
| SCHEMBL2955302 | 0.72 | BCAT2 (0.42) | FEN1ALOX5APEP300CDK2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | FEN1 2091/4885ALOX5AP 3373/4885EP300 1197/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | FEN1 2091/4885ALOX5AP 3373/4885EP300 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.